Urinary StoneNCT06083051
Differences in Postoperative Symptoms With Four Ureteral Stents
A study testing 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents and 4.8Fr Tria ureteral stents in people with Urinary Stone, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
This is a prospective randomized controlled trial designed to assess the differences in postoperative symptoms related to placement of a 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents, 4.8Fr Percuflex ureteral stents, and 4.8Fr Tria ureteral stents after ureteroscopy with laser lithotripsy for treatment of… Read more about this study
- Who is it for?
- Ages 18 to 89 years
- Conditions the study is for
- Urinary Stone
- What is being tested?
- 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents and 4.8Fr Tria ureteral stents
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 272 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Mar 2024to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 89 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with renal or ureteral urinary stones who require endoscopic treatment and stent placement in the outpatient operating room.
Who cannot join
- Pregnant patients
- Patients with transplant kidneys
- Patients with irreversible coagulopathy
- Patients with known ureteral stricture disease
- Non-English speaking, vulnerable patients such as lacking of decision-making capability, prisoner, adult unable to consent, will not be enrolled.
- Patients with planned staged procedures.
- Patients who have stent placed before surgery.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53792
About this study
Official title: Randomized Clinical Trial Evaluating Differences in Postoperative Symptoms With 6Fr Percuflex Ureteral Stents Versus 6Fr Tria Ureteral Stents Versus 4.8Fr Percuflex Ureteral Stents Versus 4.8Fr Tria Ureteral Stents After Laser Lithotripsy of Renal and Ureteral Stones
This is a prospective randomized controlled trial designed to assess the differences in postoperative symptoms related to placement of a 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents, 4.8Fr Percuflex ureteral stents, and 4.8Fr Tria ureteral stents after ureteroscopy with laser lithotripsy for treatment of upper tract urinary stones. 272 participants will be enrolled and will be on study for up to approximately 10 weeks.
Read the detailed description
The investigators will compare Ureteral Stent Symptom Questionnaire (USSQ) scores with each ureteral stent. Laser lithotripsy is a surgical procedure performed during stone surgeries. The Percuflex ureteral stent and Tria ureteral stent are FDA approved and clinically used in the United States.
A total of 3 clinic visits (i.e., pre-operative visit, the stent removal 1-2 weeks after surgery, and one post-operative visit 3-6 weeks after surgery) in addition to the surgery will be needed for this study. The patient's demographic information and medical background data will be collected from the medical record.
The USSQ will be administered twice:
- At the time of stent removal (1-2 weeks after surgery ) (This is standard of care)
- At the first postoperative follow-up after stent removal (3-6 weeks) (This is the standard of care).
The following information will be collected as secondary outcomes:
- WisQOL which will be administered three times. It is UW standard of care for stone patients to complete the WisQOL at every clinic visit.
- ER visits documented in patients chart
- Unscheduled clinic follow-up documented in patient chart
- Additional prescriptions for stent related symptoms documented by patient chart
- Stent complications by fluoroscopy or image
- Physician evaluation of the stent. Physicians will complete a one page survey at the end of the case evaluating the stent.
- Conditions
- Urinary Stone
- Being tested
- 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents, 4.8Fr Tria ureteral stents, 4.8Fr Percuflex ureteral stents
- Medical subject headings
- Urinary Calculi
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
6Fr Percuflex ureteral stentsDevice
The Percuflex stent is a 6Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
6Fr Tria ureteral stentsDevice
The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 6 Fr is the diameter.
4.8Fr Tria ureteral stentsDevice
The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 4.8 Fr is the diameter.
4.8Fr Percuflex ureteral stentsDevice
The Percuflex stent is a 4.8Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
| Study group | Role | What they receive |
|---|---|---|
| 6Fr Percuflex ureteral stents | Active comparator | Not described Receives: Device: 6Fr Percuflex ureteral stents |
| 6Fr Tria ureteral stents | Active comparator | Not described Receives: Device: 6Fr Tria ureteral stents |
| 4.8Fr Tria ureteral stents | Active comparator | Not described Receives: Device: 4.8Fr Tria ureteral stents |
| 4.8Fr Percuflex ureteral stents | Active comparator | Not described Receives: Device: 4.8Fr Percuflex ureteral stents |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ureteral Stent Symptom Questionnaire (USSQ) scores-Urinary symptoms
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The urinary subscale score range from 11-54.
Measured: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-Pain Index
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-37.
Measured: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-General Health
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The General Health subscale score range from 6-28.
Measured: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-Work Performance
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Work Performance subscale score range from 3-15.
Measured: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-Sexual matters
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Sexual Matters subscale score range from 2-10.
Measured: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-Urinary symptoms
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The urinary subscale score range from 11-54.
Measured: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-Pain index
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-37.
Measured: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-General Health
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-28.
Measured: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-Work Performance
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Work Performance subscale score range from 3-15.
Measured: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
Ureteral Stent Symptom Questionnaire (USSQ) scores-Sexual Matters
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Sexual Matters subscale score range from 2-10.
Measured: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
Secondary outcomes (6)
Change in Quality of Life measured by WISQOL Scores
WISQOL short form is a 6 item questionnaire which can be scored from 1 (worst outcome) to 5 (best outcome). The raw score range is 5-30. In the study, standardized total score is used. The range of the standardized total score is 0-100.
Measured: pre-operative visit (baseline), the stent removal 1-2 weeks after surgery (up to 4 weeks on study), and one post-operative visit 3-6 weeks after surgery (up to 10 weeks on study)
Number of Emergency Room Visits
Data collected from medical record.
Measured: up to 10 weeks
Number of Unscheduled Clinic Follow-Ups
Data collected from medical record.
Measured: up to 10 weeks
Summary of Additional Prescriptions for Stent-Related Symptoms
Data collected from medical record.
Measured: up to 10 weeks
Summary of Stent Complications
Measured: up to 10 weeks
Physician Evaluation of Stent: Survey Scores
Physicians will complete a one page survey at the end of the case evaluating the stent. Scores are from 0-5 where higher scores indicate a more positive evaluation.
Measured: up to 10 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2023
- Study start21 Mar 2024
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Urinary StoneStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 272 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ali Antar, MD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06083051
- Sponsor's protocol ID
- 2023-0832
- Other IDs
- Urology, Protocol Version 10/28/2024
- Status last verified
- Jun 2026
- First submitted
- 9 Oct 2023
- Last updated
- 8 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Clinical Trial Evaluating Differences in Postoperative Symptoms With 6Fr Percuflex Ureteral Stents Versus 6Fr Tria Ureteral Stents Versus 4.8Fr Percuflex Ureteral Stents Versus 4.8Fr Tria Ureteral Stents After Laser Lithotripsy of Renal and Ureteral Stones
- ClinicalTrials.gov ID
- NCT06083051
- Acronym / sponsor ID
- 2023-0832
- Conditions
- Urinary Stone
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 272 participants (estimated)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Study start
- 21 Mar 2024 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 13 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective randomized controlled trial designed to assess the differences in postoperative symptoms related to placement of a 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents, 4.8Fr Percuflex ureteral stents, and 4.8Fr Tria ureteral stents after ureteroscopy with laser lithotripsy for treatment of upper tract urinary stones. 272 participants will be enrolled and will be on study for up to approximately 10 weeks.
Detailed description
The investigators will compare Ureteral Stent Symptom Questionnaire (USSQ) scores with each ureteral stent. Laser lithotripsy is a surgical procedure performed during stone surgeries. The Percuflex ureteral stent and Tria ureteral stent are FDA approved and clinically used in the United States.
A total of 3 clinic visits (i.e., pre-operative visit, the stent removal 1-2 weeks after surgery, and one post-operative visit 3-6 weeks after surgery) in addition to the surgery will be needed for this study. The patient's demographic information and medical background data will be collected from the medical record.
The USSQ will be administered twice:
- At the time of stent removal (1-2 weeks after surgery ) (This is standard of care)
- At the first postoperative follow-up after stent removal (3-6 weeks) (This is the standard of care).
The following information will be collected as secondary outcomes:
- WisQOL which will be administered three times. It is UW standard of care for stone patients to complete the WisQOL at every clinic visit.
- ER visits documented in patients chart
- Unscheduled clinic follow-up documented in patient chart
- Additional prescriptions for stent related symptoms documented by patient chart
- Stent complications by fluoroscopy or image
- Physician evaluation of the stent. Physicians will complete a one page survey at the end of the case evaluating the stent.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| 6Fr Percuflex ureteral stents | Active comparator | Device: 6Fr Percuflex ureteral stents |
| 6Fr Tria ureteral stents | Active comparator | Device: 6Fr Tria ureteral stents |
| 4.8Fr Tria ureteral stents | Active comparator | Device: 4.8Fr Tria ureteral stents |
| 4.8Fr Percuflex ureteral stents | Active comparator | Device: 4.8Fr Percuflex ureteral stents |
Who may qualify
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with renal or ureteral urinary stones who require endoscopic treatment and stent placement in the outpatient operating room.
Key exclusion criteria (7 listed)
- Pregnant patients
- Patients with transplant kidneys
- Patients with irreversible coagulopathy
- Patients with known ureteral stricture disease
- Non-English speaking, vulnerable patients such as lacking of decision-making capability, prisoner, adult unable to consent, will not be enrolled.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 6Fr Percuflex ureteral stentsThe Percuflex stent is a 6Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy. | Device | 6Fr Percuflex ureteral stents |
| 6Fr Tria ureteral stentsThe Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 6 Fr is the diameter. | Device | 6Fr Tria ureteral stents |
| 4.8Fr Tria ureteral stentsThe Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 4.8 Fr is the diameter. | Device | 4.8Fr Tria ureteral stents |
| 4.8Fr Percuflex ureteral stentsThe Percuflex stent is a 4.8Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy. | Device | 4.8Fr Percuflex ureteral stents |
Primary outcome
Ureteral Stent Symptom Questionnaire (USSQ) scores-Urinary symptoms
Time frame: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The urinary subscale score range from 11-54.
Ureteral Stent Symptom Questionnaire (USSQ) scores-Pain Index
Time frame: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-37.
Ureteral Stent Symptom Questionnaire (USSQ) scores-General Health
Time frame: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The General Health subscale score range from 6-28.
Ureteral Stent Symptom Questionnaire (USSQ) scores-Work Performance
Time frame: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Work Performance subscale score range from 3-15.
Ureteral Stent Symptom Questionnaire (USSQ) scores-Sexual matters
Time frame: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Sexual Matters subscale score range from 2-10.
Ureteral Stent Symptom Questionnaire (USSQ) scores-Urinary symptoms
Time frame: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The urinary subscale score range from 11-54.
Ureteral Stent Symptom Questionnaire (USSQ) scores-Pain index
Time frame: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-37.
Ureteral Stent Symptom Questionnaire (USSQ) scores-General Health
Time frame: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Pain subscale score range from 6-28.
Ureteral Stent Symptom Questionnaire (USSQ) scores-Work Performance
Time frame: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Work Performance subscale score range from 3-15.
Ureteral Stent Symptom Questionnaire (USSQ) scores-Sexual Matters
Time frame: at time of stent removal 3-6 weeks after surgery (up to 10 weeks on study)
USSQ is a 38-item questionnaire to evaluate symptoms and impact on quality of life of ureteral stents. The high scores indicate worse outcomes. It has 5 sections, urinary symptoms, pain, general health, work performance, and sexual matters. The Sexual Matters subscale score range from 2-10.
6 secondary outcomes
Change in Quality of Life measured by WISQOL Scores
Time frame: pre-operative visit (baseline), the stent removal 1-2 weeks after surgery (up to 4 weeks on study), and one post-operative visit 3-6 weeks after surgery (up to 10 weeks on study)
Number of Emergency Room Visits
Time frame: up to 10 weeks
Number of Unscheduled Clinic Follow-Ups
Time frame: up to 10 weeks
Summary of Additional Prescriptions for Stent-Related Symptoms
Time frame: up to 10 weeks
Summary of Stent Complications
Time frame: up to 10 weeks
Physician Evaluation of Stent: Survey Scores
Time frame: up to 10 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Urinary Stone
RecruitingPhase 1/2
Dexamethasone for Ureteral STent Symptoms (DUSTS)
Ureteral Stent-Related Symptom
Not yet recruitingEarly Phase 1
Phosphate & Kidney Stones
Kidney Stones, Calcium Oxalate Kidney Stones
Recruiting
Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology
Urolithiasis, Stones, Kidney
Active, not recruitingObservational study
A Retrospective, Multi-center Real-world Study of Steerable Ureteroscopic Renal Evacuation (SURE) Procedure With the CVAC® System
Urolithiasis, Kidney Stone
Recruiting
Supervised Endoscopic Tele-controlled Intelligent Lithotripsy
Renal Stone
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ali Antar, MD principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 6Fr Percuflex ureteral stents, 6Fr Tria ureteral stents and 4.8Fr Tria ureteral stents in people with Urinary Stone, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shuang Li (608.263.8336, lis@urology.wisc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ureteral Stent Symptom Questionnaire (USSQ) scores-Urinary symptoms (time frame: at time of stent removal 1-2 weeks after surgery (up to 4 weeks on study)). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026.